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ABSTRACT 
Researchers have been trying to fight cancer with synthesis of new bioactive 
compounds but many of these novel drugs have low solubility in water and it is difficult 
to deliver them into a patient's body One way of solving this particular problem is to 
use nanoscale drug delivery systems In this dissertation, we describe using an 
ultrasonic assisted layer-by-layer encapsulation process to prepare anti-cancer drugs 
with 50-200 ran particle size with designed coating to achieve sustained release and 
target delivery 
Two methods for systematic manufacture of low solubility anti-cancer drug 
nanoparticles were proposed 1) Top-down approach to breakdown larger drug crystals 
into nano-size particles 2) Bottom-up approach to fabricate nano size drug crystals 
from a drug solution 
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CHAPTER 1 
INTRODUCTION 
1 1 Motivation 
Cancer is the second leading cause of death in the Umted States The National 
Cancer Institute estimated that 1,529,560 men and women (789,620 men and 739,940 
women) will be diagnosed with, and 569,490 men and women will die from various of 
cancer m 2010 [1] 
Researchers had been trying to fight cancer with new natural or synthetic 
bioactive compounds Although these novel compounds showed promising results in 
screening process, many of them exhibit low solubility in water because of the 
hydrophobic and/or polycychc nature Low solubility often brings challenges to drug 
administration, because the traditional formulation usually cannot provide enough of the 
bioavailability required for treatment Also many of these compounds are highly toxic 
to normal cells so targeted delivery of the drug to the tumor tissues is required One way 
of solving the problem is to establish a drug delivery system that uses nano size drug 
particles with appropriate coating Our project will use an ultrasonic assisted layer-by-
layer encapsulation process to prepare anti-cancer drug with 50-200 nm size with a 
designed coating to achieve sustained release and targeted delivery 
1 
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1.2 Outlines 
1.2.1 Objectives of the study 
We developed the following directions in our work 
1 We will systemically establish a process to fabricate nano size, low solubility 
drug particles (pachtaxel and curcumin) 
2 We will optimize the process established m 1 to reduce the drug particle size 
3 We will compare different layer-by-layer coatings for sustained release 
1.2.2 Outline of the dissertation 
This dissertation is arranged into eight chapters Chapter 1 provides an 
introduction to the dissertation by describing the motivation and purpose of the study as 
well as the outline of the dissertation Chapter 2 is the literature review, m which we 
will discuss nanoscale drug delivery systems m general and compare different types of 
existing nanoscale drug delivery systems This is followed by a short introduction to the 
layer-by-layer self-assembly coating drug delivery system In Chapter 3, we mtroduc 
the material, instruments, and general methods that were used in this research Chapter 
4 is focused on the top down approach which breaks down big drug particles into nano 
size particles Chapter 5 will show a different bottom up approach which forms nano 
crystals from solution using ultrasound Chapter 6 will optimize particle size by 
changing various parameters, like somcation time and concentration Chapter 7 will 
study the release profile of different nano drug particles The main accomplishments of 
the dissertation work are summarized in Chapter 8, with directions for further research 
CHAPTER 2 
NANOSCALE DRUG DELIVERY SYSTEM 
2.1 Nanoscale Drug Delivery System 
With the application of nanotechnologies to medicine, a new branch of 
nanotechnology, called nanomedicine, has been rapidly developed [2] Nanoscale drug 
delivery systems use nanosize drug carriers to deliver drugs to the desired sites And 
often use active or passive targeting strategies to increase local concentration at the 
tumor tissue [3] 
Goals of a nanoscale drug delivery system include 
1 Improved solubility To increase the drug bioavailability 
2 Targeting To increase the local concentration of the drug at desired sites 
3 Adjustable rate of drug release To maintain a constant dose at the action site 
4 Reduced drug clearances To increase the drug half-life 
5 Enhanced stability To reduce drug degradation dunng storage 
6 Drug delivery across biobarners like the blood-brain barrier (BBB) 
The goals of the drug delivery system were to deliver the conjugated or bound 
drug-carrier complex to the selected target and maximize act at desired cancer sites 
Controlled delivery of the drug molecules using carrier materials are based on two types 
of strategies active and passive targeting Although the former has very sophisticated 
strategies, its practical use still suffers from many technical difficulties The latter is 
3 
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more practical, and there are already many formulations based on "enhanced 
permeability and retention effect" [4, 5], which has been the most representative 
passive-targeting strategy to bring drug molecules to tumors 
The active targeting strategy of the drug nanocarrier was to use a hgand, 
attached on the nanocarrier, specific for the receptor of the target tissue Passive 
targeting strategy of the drug nanocarrier was to use the enhanced permeation and 
retention (EPR) effect of the cancer tissue Tumor and inflamed tissue tend to have 
excessively leaky microvasculature, compared to normal endothelium, which allows the 
drug nanocarrier to diffuse through and accumulate at site Especially for cancer tissue, 
overexpression of vascular endothelial growth factor will increase vascular 
permeabhhty and let to complicated tumor-vessel architecture Transvasation of durg 
carrier takes place either via transcytosis, where by macromolecules are internalized 
from the blood at points of invagination of the cell membrane, or paracellularly, via 
diffusion through the tight junctions of endothelial cells In combination, these effects 
cause enhanced permeation and retention (EPR), resulting m high local drug 
concentrations 
For nanoscale drug delivery systems, biocompatibihty and biodegradability have 
always been considered as one of the most important propenties The unloaded carrier 
should be able to biodegrade or metabolize into nontoxic components and cleared 
through the circulation system Some studies suggested nanoparticles are cleared 
according to size Small particles (<30 nm) are rapidly cleared by renal excretion 
Nanocarriers >30 nm are cleared by the mononuclear phagocytic system, consisting of 
macrophages located m the liver (Kupffer cells) and the spleen [6], which act as 
phagocytotic scavengers Clearance is also dependent on the endothelial fenestral pore 
size [6] Fenestral pore size values are highly variable for different patients Clearance 
rate of patient could be effect by sex, age and genetics factors It is difficult to 
determine the efficiency and toxicity of nanomedicines m different individuals Whether 
nanocarriers are taken up by macrophages depends on opsomzation by the innate 
immune system [7] Molecules that bind to foreign materials and enhance phagocytosis, 
include IgG and IgA antibodies, the complement cascade system and mannose-binding 
lectin [8] Therefore, the surface properties of nanocarriers can significantly affect the 
rate of clearance by the MPS A useful method for evading opsomzation of large narrow 
carriers was developed at Rutgers University [9] in a process call PEGylation, a 
polymer, poly(ethylene glycol) (PEG, [CH2CH20]n), is conjugated to the drug carrier 
preventing drug particles aggregation and precipitation 
Overall, the use of hgand binding nanodrugcarner will improve the drug 
therapeutic index according to Equation (1) 
_, , Maximum non - toxic dose 
Therapeutic index = 
Minimum effective dose ngq 1) 
The high specificity and selectivity of the hgand on nanodrugcarner increases 
the amount of drug delivered to the cancer tissue and decreases the amount of drug at 
unwanted sites Therefore, a less systemic drug dose needs to be admimstered to 
guarantee an effective concentration at the site of action, and the mimmum efficacious 
dose is also lower In addition, because less drug is present at unwanted sites, the 
maximum non-toxic dose is higher The overall effect is a sigmficant decrease in 
toxicity and adverse side effects 
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2.2 Current Nanoscale Drug Delivery System 
Nanoscale drug delivery systems can use different kind of nanoparticles as 
carriers In this section we will review some of the most common category of 
nanoparticles can be used as drug delivery systems Figure 2-1 shows the structure 
schematics of these nanoparticles 
Therapeutic agent Targeting agent 
Figure 2-1 Classification of nanoscale drug delivery System 
a) drug conjugate, b) dendnmer, c) micelle, 
d) microemulsion, e) vesicle, f) core-shell nanoparticle, 
g) nanotube 
2 2 1 Drug complex and conjugate 
Drug complexes and conjugates do not have a defined structure like micelle or 
vesicle Drug complexes depend on reversible interactions between carrier and drug 
7 
Drug conjugates use covalent bonds to join carrier and drug together [10] Drug 
conjugates can be prepared using chemical reactions of functional groups between the 
drug and the earner molecular There are two major categones of drug complexes and 
conjugates one is protein and peptide associated and the other is polymer associated 
Proteins and peptides can be used to form nano structures in vanous ways, including 
complexation An example of protein associated drug complex nanoparticle for clinical 
use is Abraxane™ Abraxane is an albumin-bound form of pachtaxel with a mean 
particle size of approximately 130 nanometers Pachtaxel exists in the albumin-bound 
particles in a non-crystalline form Abraxane™ is formed by dissolving pachtaxel in 
water immiscible methylene chloride, and adding this to a solution of human serum 
albumin in water with low-speed homogemzation This process creates an emulsion 
with albumin located at the aqueous-solvent interface Subsequent high-pressure 
homogemzation reduces the particle size and breaks and reforms the disulfide bonds, 
essentially crosshnking the albumin coating and stabilizing the particle An evaporation 
step volatilizes the methylene chlonde, leaving an aqueous suspension of 140-160 nm 
nanoparticles, consisting of an amorphous pachtaxel core sunounded by a 25 nm 
coating of albumin with bound pachtaxel Because of its size this matenal can be sterile 
filtered [11, 12] Abraxane7 does not contain the problematic solvent - Cremophor EL, 
which outperformed conventional pachtaxel at an equitoxic dose while decreasing 
toxicity, due to longer circulation time and lower off-target activity [13, 14] 
Supramolecular complexes between host and guest molecules are also considered as 
useful for the drug administration Cyclodextrms are natural products and can entrap 
entire or part of guest drugs in their inside cavity in a specific mode Chemical 
modification of natural cyclodextrms molecular could improve their efficacy by altenng 
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their solubility or capacity for the guest drugs Cyclodextrms are regarded as useful 
additive in drug delivery systems [15, 16] 
2.2.2 Dendnmer 
Polymenc dendnmer is a kind of hyperbranched nanostructures One of 
dendnmers' advantages is that its size can be controlled by adjusting the number of 
polymenzation generations Dunng the polymerization progcess, monomer molecules 
joined into a sphencal nanostructure Inside this dendnmer nanostructure are cavities 
which allowed therapeutic agents to be loaded with great loading efficiency [17] 
The polymenzation progresses of dendnmers can be precisely controlled to 
obtain the desired final product The molecular weight, chemical composition, and 
nanostructure of the final product can be precisely designed [18] With controlled 
polymer structure and narrow polydispersity, dendnmers may be ideal platforms for 
drug delivery system An example of dendnmers for clinical usage is VivaGel ™ It is 
currently on tnal for safety and efficacy as a microbicide 
2.2.3 Micelles 
Micelles are one of the simplest molecular assemblies and can carry 
hydrophobic drugs in their central core or m their palisade layer [19] Micelles 
nanoparticles are interesting structures for earners of drugs because they can form 
relatively uniform size structures Micelles can be formed using a variety of amphiphihc 
materials as outside coating and using hydrophobic drug as central core, and can 
incorporate multiple functionalities into a single structure Unfortunately, surfactants 
used to form micelles often have toxic effects on human bodies Only a few kinds of 
surfactant are approved by FDA for drug solubilization Additional use of organic 
solvents may increase drug solubility but disturbs micelle formation in some cases [20, 
9 
21 ] Lacking an aqueous core, the drug must be bound to the polymer before micelles 
formation Drug needs to be conjugated to an anchor polymer molecule, or entrapped 
and bonded inside the hydrophobic core of the micelle [22] Micellar structures, 
including polymenc micelles, have been extensively studied as drug earners [23] 
Polymeric micelles made of hydrophihc-hydrophobic block copolymers are used as 
drug earners [34] which can be concentrated in the tumor tissue based on the EPR effect 
[25], and may be used for gene therapy as well [26] Because hydrophihc-hydrophobic 
block copolymers' cntical micelle concentrations are much lower than those for low-
molecular-weight surfactants, they have higher stability and lower toxicity The 
hydrophobic portion of the copolymer forms the micellar core The hydrophihc block of 
the copolymer forms the micellar corona This corona (commonly consisting of PEG, 
HPMA, or other hydrophihc polymers) confers these micelles with biocompatibihty, 
stealth-like properties, and a platform for functionahzation [27-29] Genexol-PM is a 
formulation of pachtaxel encapsulated in a polymenc micelle formed by the solid 
dispersion technique from the biodegradable block copolymer, monomethoxy 
poly(ethylene glycol)-block-poly(D,L-lactide) [30] Several climcal trials have already 
been carried out evaluating the safety and efficacy of Genexol-PM™ m metastatic 
breast cancer, solid tumors, and non-small-cell lung cancer [31-33] 
2.2 4 Microemulsion 
Entrapment of drugs within emulsions [34] results in vanous improvements in 
the performance of the drugs including suppression of side effects, prolonged drug 
retention in blood circulation, and enhanced drug efficacy at the target site based on the 
EPR effect Lipid emulsions have a long history m the pharmaceutical practice as 
nutnents, commercialized emulsion formulation was achieved relatively easily by 
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incorporating hydrophobic drugs, such as steroids, into the traditional emulsions 
Microemulsion is an equilibrated solution, unlike emulsions, and it is utilized for oral 
formulations [35-37] Formulations containing surfactants, drugs, and oils, which were 
designed to spontaneously form microemulsions upon contact with water in the stomach 
and small intestine, induce reproducible drug release This formulation offers great 
contribution to organ transplantation [38], since it requires precise control of the 
immunosuppressant concentration in plasma Microspheres composed of appropnate 
polymers, such as biodegradable polymers, enable prolonged drug-release after 
intravenous injection Administration frequency has decreased from daily to monthly by 
using this earner [39] 
2.2.5 Vesicles 
Vesicular structures have been extensively studied as drug delivery system The 
two major categories of vesicles are liposomes and polymer vesicles Vesicles have the 
capacity for encapsulation of hydrophobic or hydrophihc drugs Vesicles can be design 
to use covalent or non-covalent bonds to load drugs Liposomes, (or lipid vesicles) [40] 
can be used to load hydrophihc drugs into an intenor aqueous phase Liposomes can 
also be used to load hydrophobic drug lipid phase in the shell Liposomes are 
considered to be ideal drug earners, because of their surface characteristics can be 
altered easily and their size is controllable Use of liposomes as a climcal drug delivery 
system still need to face some technical difficulties like mass production, storage 
stabilities, and lack of efficacy after accumulating a the target site Recently, liposomes 
have also been studied as non-virus vectors for gene therapy [41] Liposome 
formulations for drug delivery have been in development for almost half a century, and 
have produced climcally successful applications [42] Polymenc vesicle structures, or 
11 
polymersomes, have been described more recently, and have unique potential as drug 
earners An example of the climcal vesicle formulation is Doxil ™, also known as 
liposomal Dox Encapsulation of Doxorubicin in liposomes shielded by polyethylene 
glycol (PEG) prolongs systemic drug circulation, improves safety, and increase the 
therapeutic index relative to free Doxorubicin [44,45] 
2.2.6 Core-shell nanoparticles 
Core-shell structured nanoparticles consist of an inner nanoparticle core and a 
hydrophihc shell The inner nanoparticle core could be made with a wide vanety of 
matenals including Quantum-dots, metals, metal oxides, and polymers among other 
materials The core is sunounded by a hydrophihc shell usually using covalent or lomc 
bonds or electrostatic force 
One category of core-shell nanoparticles has been developed during the 
chemical modification of gold and other materials nanoparticles to increase their 
physiological stability and control drug association and release [46] These core-shell 
nanoparticles offer stability and modifiable surface properties, and can even produce 
contrast depending on their composition, size, and shape [47, 48] These core-shell 
structured nanoparticles make for a very robust drug delivery vehicle due to the vast 
variety of elements that can be used as the core and shell components Despite the 
advantages already mentioned, these core-shell nanoparticles suffer from some inherent 
shortcomings, such as biotoxicity, rapid clearance rate, and poor biodistnbution and 
biodegradation Various strategies are in development to circumvent these problems 
[49, 50] 
Another category of core-shell nanoparticles uses porous materials as an inner 
core to cany drug Porous matenals with large surface area and pore volume are 
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regarded as good candidates for drug storage and delivery As a example, mesoporous 
silica have been investigated as a drug earner materials because of its mesochannels, 
which have defined diameters in the ranges of nanometers to tens of nanometers provide 
reliable nanospaces for drug accommodations [51, 52] In addition, their huge pore 
volume per unit mass of matenals enables us to entrap large amounts of drugs In some 
pioneenng approaches, the inlets of channels are modified to add gate functions, 
resulting in controlled release by external stimuli [51-53] Not limited to mesoporous 
silica, mesoporous carbon and related matenals [54, 55], biocompatible porous calcium 
phosphate [56], and metal-organic frameworks (MOF) [57] have also been paid 
attention as future strong candidates for drug delivery applications 
2.2 7 Nanotubes 
Carbon nanotubes are used as drug earners because of their nanocavities and 
high surface area [58, 59] However, there is much concern regarding the long-term 
toxicity of the nanotubes in practical uses due to their geometrical similarity to asbestos 
[60] Carbon nanohorns may be a better candidate for drug earner [61] due to theirs 
lower aspect ratio, which is considered to play important role in the toxicity Carbon 
nanotubes (CNTs) are cyhndncal tubes composed solely of carbon and can be formed 
either as single-walled or multi-walled, for more stability [62] These CNTs are being 
investigated as therapeutic nanoparticles because of their tunable properties and ability 
to incorporate multiple functionalities Amine-functionahzed, single-walled CNTs were 
conjugated by amide-linking to a cisplatm-fohc acid derivative as targeted delivery 
system, has show better performence than a conventional cisplatin formulation [63] 
Another study conducted by Rushng et al used carboxylated single-walled 
CNTs conjugated with cisplatin and epidermal growth factor to target cancer cells 
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which have overexpress of the epidermal growth factor receptor The targeted CNT-
cisplatin conjugate improved the selective killing of the targeted tumor cells [64] Many 
studies have reported CNTs to be effective earners of therapeutics and imaging agents 
in vitro, however, in vivo studies have lead to concerns regarding the associated 
toxicities [65-67] 
An interesting development was recently reported on drug delivery with 
halloysite clay nanotubes [68-71] These clay nanotubes have a larger diameter than 
carbon nanotubes (ca 50 nm external diameter, 15 nm lumen diameter and length of ca 
800 nm), and they are biocompatible [72] Drugs may be loaded into these tubes within 
a minute at ca 10-20 wt % and then slowly released over 10-50 hours [69] It is not 
assumed that it would be possible to inject halloysite clay nanotubes into the blood 
stream, due to their inorganic composition, but their applications for dermatological 
(including rectal), cosmetic and dental delivery were considered as well as 
incorporation into bone and tooth implants 
2.3 Layer-by-layer Coated Nanoparticles for Drug Delivery 
2.3.1 Outline of LbL assembly 
Before we discuss the LbL capsules for drug delivery we will first briefly review 
the layer by layer self assembly technique in this section [73, 74] Self-assembly of the 
nano particles using electrostatic interactions through a layer-by-layer process, was first 
proposed by R K Her [75] The idea was developed and first realized by Decher, 
Mohwald, Lvov, et al [76, 77] Because the self assembling mechanism is so simple, the 
requirements for the apparatus necessary for the process are very low (requiring only 
beakers and tweezers) [78], and the procedures are easy to perform, this methodology 
was quickly adapted by many research groups with the utilization of layer by layer 
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assemblies of various materials including synthetic polymers [79-80], biomaterials [81-
84], inorganic materials [85-87], and supra-molecular assemblies [88-90] Relatively 
high concentrations of the charged substances in the solution results in excess 
adsorption of the substances The surface charge was first neutralized and then 
resaturated lead to charge reversal (Figure 2-2) Reversing of the surface charge makes 
a continuous assembly between positively and negatively charged matenals The 
driving forces for the LbL self-assemblies are not limited to electrostatic interactions 
Many kinds of interactions , such as metal coordination [91, 92], hydrogen bonding [93, 
94], covalent bonding [95, 96], supramolecular inclusion [97], bio-specific recognition 
[98, 99], charge transfer complex formation [100], and stereo-complex formation [101, 
102] were reported and could be used in the LbL process Many other deposition 
techniques including spin-coating [103, 104] and spraying [105], were used for the LbL 
assembly Also automatic machines were developed for the LbL assembly [106, 107] 
The matenals used for LbL assembly also have been widely tested In the 90's, most 
researchers used synthetic polyelectrolytes, such as PAH, PEI, PDDA, PSS and PAA, 
but cunent research, especially related to biomaterials and pharmacology, uses natural 
biodegradable polyelectrolytes, including positively charged chitosan, dextran amine, 
gelatin A, protomme sulfate, and negatively charged chondroitin sulfate, dextran 
sulfate, hyaluronic acid, hepann, gelatin B and sodium alginate 
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Figure 2-2 LbL assembly process outline 
The LbL assembly techniques are considered suitable for biomaterials, because 
the process is simple and is performed m mild environment The LbL assembly is 
usually performed at room temperature in a pH neutral aqueous solution Because the 
LbL technique does not require special conditions like high temperature or extreme pH, 
biomaterials can be assembled under favorable conditions Another advantage of the 
LbL assemblies for biomaterials is the porous nature Unlike Langmuir-Blodgett (LB) 
films, LbL films allow diffusion of matenals Activities of the enzyme glucose oxidase 
were reported to be blocked after covering with only a few layers of lipid LB films 
[108, 109] The LbL films with a single component enzyme (glucose oxidase) or 
multiple enzymes (glucose oxidase and glucoamylase) do not have a senous decrease in 
enzyme activity after an increase m the numbers of layers [110, 111] These facts show 
that LbL films allow the diffusion of materials This ability is a crucial factor in drug 
delivery functions Additionally, it was also reported that biomaterials embedded withm 
the LbL films show better stabilities [112] 
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An important development in the LbL technique was applying LbL technique to 
assembly on colloidal particles [113] This technique was first developed by G 
Sukhorukov, E Donath, F Caruso, and H Mohwald in the Max Planck Institute for 
Colloids and Interfaces [113-122], and then was quickly adapted by other groups 
Instead of using conventional flat surface supports, LbL films were assembled 
sequentially on a colloidal core Subsequent destruction of the central colloid particle 
core could lead to hollow shells A typical example of preparing functional hollow 
shells is shown in Figure 2-3 where DNA molecules, retaining the natural double-helix 
structure, were encapsulated inside a biocompatible polyelectrolyte microshell [123, 
124] In the first step, MnC03 particles were used as template, cores were suspended in 
a DNA solution, and the addition of spermidine solution into stmed MnC03/DNA 
solution caused precipitation of a water-insoluble DNA/spermidine complex onto the 
MnC03 particle Then in the second step, LbL assemblies of biocompatible 
polyargimne and chondroitin sulfate on the complex core were conducted In the third 
step, dissolution of the MnC03 template particles resulted in biocompatible shells 
contaimng a DNA/spermidine complex In addition, further decomposition of the 
DNA/spermidine complex led to a selective release of low molecular weight spermidine 
to complete the DNA entrapment In another example, De Smedt and coworkers 
reported a labeling system for LbL drug delivery using the barcode concept with 
encoded fluorescent polystyrene with captured antibodies [124] 
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Figure 2-3 Preparation of functional hollow shells 
2 3.2 Recent progress of LbL microshells in drug delivery functions 
The LbL microshells could be used in many applications including in life 
science [125-127] The LbL microsells used as drug earners have been attracting a lot 
of attention Most LbL shells used in these applications have diameter at micrometer 
range Raichur et al reported encapsulation and release profiles of rifampicin, an 
antituberculosis drug, using hydrogen-bond assembly LbL microshells of poly(vinyl 
pynohdone) and poly(methacryhc acid) [128] Release profiles showed a burst release 
Above pH 7, the maximum release rate was achieved because the microshells rapidly 
disintegrate The nfampicm released from the LbL microshells shows the same efficacy 
as the free drug This result indicates the drug properties have not changed because of 
possible disturbances during the encapsulation and release process Zhao, et al reported 
the loading of doxorubicin, an anti-tumor drug, into preformed LbL microshells The 
doxorubicin loaded LbL microsells' effect in tumor treatment was assayed by in vitro 
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cell culture tests and in vivo animal experiments [129] The LbL microshells contain 
negatively charged carboxylmethyl cellulose which entraps levels of the positively 
charged doxorubicin ten to a hundred times higher than the feeding concentration The 
encapsulated doxorubicin can effectively trigger the apoptosis of HepG2 tumor cells on 
in vitro tests The result shows that the LbL microshells have the ability for drug 
delivery and cancer treatment on an animal expenmental level Chen, et al encapsulated 
another anti-cancer drug artemisinin in the crystal form with LbL microshell containing 
chitosan, gelatin, and alginate using LbL technique [130] The release rate of 
artemisinin could be adjusted by various parameters, such as polyelectrolyte types, 
number of polyelectrolyte layers, sodium chloride concentration, and ethanol 
concentration in the polyelectrolyte solution 
Many researchers also try to control of drug release using external stimulaton 
Zhang, Gu, et al synthesized alginate-templated magnetically sensitive LbL microshells 
[131] When a high-frequency magnetic field was applied, doxorubicin's drug release 
rate from the microshells was significantly increased The doxorubicin-loaded 
microshells showed much lower cytotoxicity at the high drug concentration in 
comparison with doxorubicin Choi et al prepared LbL microshells containing 
photoacid generators, which made them UV sensitive [132] UV light will induce 
activation of photoacid generators and lead to the release of protons The decrease in the 
pH of the solution tnggered the swelling of the LbL microshells Thus, opemng and 
closure of the LbL microsell was achieved by exposure to UV light and washing with 
pH neutral water In addition, prolonged UV light exposure led to the breakage of the 
LbL microshells, which results in rapid release of the entrapped drugs 
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Protein delivery using LbL shells is also an active area in cunent research 
Zhang, Li, et al reported encapsulation and controlled release of protein using 
biodegradable LbL microshells The microshells consisted of dextran sulfate and 
chitosan Bovine serum albumin (BSA) was used as the model protein BSA was 
encapsulated in the LbL shells [133] The cell viability test indicated that the LbL 
microshells had good biocompatibihty De Geest, Parak, et al encapsulated with a 
model of a nonactive prodrug, a self-quenched fluorescence-labeled protein in 
biodegradable LbL microshells [134] After the microshells uptake by living cells, the 
walls of the microshells were degraded and digested by intracellular proteases Wall 
degradation allowed intracellular proteases to reach the protein loaded inside of the 
microshells Enzymatic fragmentation of the fluorescence-labeled protein leads to 
individual fluorescence-labeled peptides So, only prodrugs inside the microshells that 
reach into the cells are the only ones activated, and those in shells in the extracellular 
environment cannot be activated Akashi et al reported entrapped proteins inside 
biodegradable microshells via LbL assembly Chitosan and dextran sulfate were 
assembled onto a protein-entrapping mesoporous silica particles, and then the silica was 
subsequent dissolved [135] Sustained release of the encapsulated proteins was achieved 
by using the enzyme to degrade the hollow shells 
Variously specifically designed polymers have been used to compose the LbL 
microshells For example, Vancso et al developed organometalhc polyelectrolyte 
multilayer microshells, which are composed of polyanions and polycations of 
poly(ferrocenylsilane) (Figure 2-4) [136] Poly(fenocenylsilane) have redox-active 
fenocene units in the main chain, which makes the shell wall permeability sensitive to 
the redox state In fact, the permeability of these microshells can be tuned using 
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chemical oxidation, resulting in a fast shell expansion accompanied by a significant 
permeability increase in response to a very small trigger 
Figure 2-4 Organometalhc polyelectrolyte multilayer microshells, 
composed of polyanions and polycations of 
poly(fenocenylsilane) 
Caruso et al developed a new type of polymer hydrogel LbL microshells based 
on disulfide cross-linked poly(methacryhc acid) and poly(vmylpynohdone) The 
disulfide cross-linking is sensitive to redox state It can act as redox-active tngger for 
shell degradation [137] They also developed degradable LbL microshells as drug 
earners for the delivery of oligopeptide antigens to antigen presenting cells (Figure 2-5) 
[138] Oligopeptide sequences were first covalently linked to a negatively charged 
polymer via biodegradable linkages Then this conjugate was adsorbed onto amine-
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functionahzed silica particles The peptide-coated particle was coated with thiolated 
poly(methacryhc acid) (PMASH) and poly(vinylpynohdone) (PVPON) Dissolving of 
the silica core and disruption of the hydrogen bonding between polymers resulted in 
disulfide-stabihzed microshells Glutathione, a natural reducing agent, can be used to 
cut the disulfide bonds which causes release of the peptide from the microshells 
Figure 2-5 Degradable polymer microshells as earners for the 
delivery of oligopeptide antigens 
Many researchers combine of the LbL technique with other molecular assembly 
technique, such as liposomes or micelles, together to create various shell systems 
Addison et al develpoed LbL microshells constructed entirely from a cationic/ 
zwitteriomc pair of pH-responsive block copolymer micelles [139] Layers of aniomc 
poly[2-(dimefhylamino)efhyl methacrylate-hlock-poly(2-(diethylamino)ethyl metha-
crylate)] and cationic poly(2-(diethylamino)ethyl) methacrylate-block-poly(meth-
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acrylic acid) copolymer micelles were alternately assembled onto CaC03 colloidal 
templates Then add in dilute ethylenediaminetetraacetic acid solution to dissolve the 
CaC03 core and form hollow polymer microshells This type of LbL microshells is 
composed entirely by pH sensitive block-copolymer has potential application for the 
encapsulation and tnggered release of drugs Li, Hu, et al fabncated via a layer-by-
layer technique, templated on CaC03 particles with built-in polymeric micelles based 
on polystyrene-b-poly(acryhc acid) [140] This type of LbL microshell can selectively 
entrap positively charged substances such as rhodamine B and lysozymecan The 
positively charged substances can be entrapped in the shells where the concentration is 
much higher than that in the incubation solution The encapsulated compounds shown 
sustain released to a certain degree, as suggested by in vitro release experiments Caruso 
et al reported using micelles for LbL assembly They synthesis DNA-grafted poly(N-
lsopropylacrylamide) (PNIPAM) micelles, then assembly PNIPAM micelles into LbL 
films, and then use poly(ethylene glycol) (PEG) to functionahze the DNA-PNIPAM 
microcapsules [141] The combination of hydrophobic core and alkyne "click" groups, 
along with the biodegradabihty of DNA, offers a multifunctional and versatile 
DNA-polymer capsule system that can be used for the controlled delivery of 
therapeutics 
Fukui and Fujimoto combined the liposome preparation and the LbL deposition 
together to prepare hollow shell structures [142] Chitosan was deposited onto a 
negatively charged liposome surface and form a cationic polymeric layer Then dextran 
sulfate or deoxyribonucleic acid was used to form an aniomc polymers layer They 
reported that chemical substances with different charges, alendronate, pyranine, and 
glucose, were encapsulated into microshells where the release rate was suppressed by 
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the polymer shell wall inespective of charges [142] Also they use DNA denaturation as 
a temperature dependent switch to achieve the temperature-dependent release Tabnzian 
et al developed a delivery system for bone growth factors consisting of a liposome core 
incorporated into a shell of LbL-assembled natural polyelectrolytes [143] The prepared 
hydrophihc, monodisperse, spherical and stable cationic nanoparticles (< or =350 nm), 
as a delivery system, localized the effect of the released bone growth factors within the 
site of injection in muscle Ramaye et al developed a combination of magnetic 
liposomes and LbL assembling techniques [144] Superparamagnetic nanoparticles were 
encapsulated in liposomes prior to the stepwise adsorption of LbL assembly Magnetic 
field also allows a fast separation of coated liposomes from unbound polyelectrolytes 
The presence of magnetic nanoparticles and the polyelectrolyte shell opens allows to 
use external magnetic field to manipulate and target drug earners 
Integrated shell structures have also been proposed De Smedt et al designed 
self-exploding gel beads that can release micrometer-sized shells at the time of 
explosion (Figure 2-6) [145] The larger gel beads were loaded with small LbL 
microshells When the polyelectrolyte coated gel beads explode under alkaline 
conditions, through rapid hydrolysis of the carbonate esters connecting the polymerized 
methacrylate groups with the dextran backbone, the smaller LbL microshells become 
suddenly released Self-exploding gel beads releasing antigen containing LbL 
microshells at different times after injection could become promising materials for 
vaccination purposes The reverse-phase was used to coat polymer layers onto agarose 
microbeads contaimng tns-buffer for the formation of LbL shell-walls onto the 
microbeads The polymer-coated agarose microbeads were transfened from an organic 
to an aqueous solvent where the tns-molecules induced an osmotic pressure in the 
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microshells' interior The inflation of the LbL microshells caused the expansion of the 
LbL shell-walls The inflated microshells can control localized chemical or enzymatic 
reactions that are useful in biomedical applications Ke, et al developed a bi-mode 
ultrasound/fluorescent imaging agent through LbL assembly of poly(allylamme 
hydrochlonde) (PAH) and CdTe quantum dots onto microbubbles produced by 
somcation of a mixture of Span 60 and Tween 80 [147] The Quantum-dot-modified 
microbubbles not only maintained the ability of ultrasound imaging, but also could used 
as a targeted-drug controlled-release system to deliver the quantum dots by ultrasound 
targeted microbubble destruction 
Small LbL Shell I 
LbL Shell 
Figure 2-6 Self-exploding polyelectrolyte coated gel beads 
releasing micrometer-sized shells at the time of 
explosion 
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In conclusion for Chapter 2, layer-by-layer (LbL) nanoassembly is a simple 
method allowing the design of multilayer architectures with nanometer precisions It is 
based on the alternate re-saturated adsorption of oppositely charged components, such 
as synthetic and natural polyelectrolytes, proteins and nanoparticles The only rule of 
thumb is sequential adsorption of positively and negatively charged components 
resulting in any pre-determmed composition multilayer film One forms films 
consisting of bilayers of electrostatically bound cationic and anionic macromolecules, 
and the typical bilayer thickness is one to a few nanometers Following the first LbL 
papers published in the beginning of the mneties by G Decher, H Mohwald, Y Lvov, 
M Rubner and others, one can find around 8,000 publications dealing with the LbL 
technique It is interesting that until the last few years, the majority of these works were 
devoted to LbL assembly predominantly using sodium poly(styrene sulfonate) - PSS, 
poly(allylamine) hydrochlonde-PAH and poly(ethyleneimine)-PEI These PSS, PAH, 
and PEI multilayers are the most studied, but, in recent years, researchers began using 
natural polyelectrolytes and proteins Now, one can conclude that the LbL method 
works perfectly for the assembly of aniomc compounds, such as alginic acid, hyaluronic 
acid, chondroitin sulfate, heparin, dextran sulfate, carboxymethyl cellulose, 
polyanunoacids, DNA, and catiomc ones chitosan, dextran amine, polylysine, 
collagens, protamine sulfate, gelatin A, and others Therefore, we have a group of 
biocompatible and biodegradable materials (in many cases FDA approved) and the 
LbL-techmque to assemble them in a controllable manner in multilayers of 2-500 nm 
thickness 
How can these architectural multilayers be used for drug delivery*? An answer is 
by formation of microcapsules loaded with drugs Formation of LbL multilayers on tiny 
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templates and performing LbL encapsulation was first introduced in 1999 in Max 
Planck Institute, Germany by G Sukhorukov, E Donath, F Caruso, H Mohwald and Y 
Lvov Generally, LbL encapsulation is the same method as described above for a planar 
substrate but applied to small 2-5 micrometer diameter drug particles or sacrificed 
polymeric, MgC03, CaC03 or silica cores The possibility to design any thickness or 
composition of such LbL shells allowed control of drug diffusion from the capsules For 
different drugs, the vanation of the capsule wall thickness within 20-100 nm allowed 
release time from 10 mm to 5 hours This is the mam idea for LbL encapsulation for 
controlled drug delivery 
Cunently, one can indicate two methods in LbL encapsulation 1) The more 
common approach for formation of LbL microcapsules on sacnficed cores, dissolution 
of such cores and loading empty LbL microshells with drugs or proteins through a pH 
dependable capsule wall pore opemng In this case, drug loadmg is 5-10 % The 
following drugs were analyzed for LbL encapsulation lbuprofen, furosemide, 
nifedipine, naproxen, biotin, vitamin K3, insulin, dexamethasone, tamoxifen, pachtaxel 
2) The second direction is much less known (only four publications exist from LaTech's 
group) using the LbL nanoencapsulation of low soluble drug nanoparticles (which 
allowed ca 70-80 % drug loading) 
Therefore, in LbL capsules one can see two tendencies Making microcapsules 
with sophisticated multifunctional shells of contaimng 5-10 wt % of drugs and having 
the ability for switchable release with few to tens of hours In most of the recent 
published papers, such LbL capsules have a diameter of a few micrometers It appears 
to be too large for blood injection but these LbL microcapsules have a very thin flexible 
wall and they have a certain ability to squeeze through nanow capillaries similar to 
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blood cells Another tendency is making very thin LbL-shells (two-three 
polyelectrolyte layers of 5-10 nm) on 100-200 nm diameter cores of low soluble drugs 
(often anti-cancer drugs) In this encapsulation, LbL coating provides a strong surface 
charge producing stable nanocoUoids of initially poorly soluble matenals It is this 
second approach for low solubility cancer drug nanoformulations that will be further 
developed in this dissertation 
CHAPTER 3 
INSTRUMENTATION AND MATERIALS 
LbL assembly was earned out using polyallylamine hydrochloride (PAH), 
polyethylemeimine (PEI), protamine sulfate and chitosan, as positively charged 
polyelectrolytes and bovine serum albumin (BSA), algimc acid, and sodium polystyrene 
sulphonate (PSS), as negatively charged polyelectrolytes (used at concentration of 2 
mg/mL) All polyelectrolytes and albumin were purchased from Sigma-Aldnch except 
pachtaxel is purchased from LC Laboratones Inc (Woburn, MA), curcumin is provided 
by Sabmsa Corporation (East Windsor NJ) Deiomzed water and phosphate buffered 
saline (PBS) buffer were used at pH 7 2 Ultrasonicator UlPlOOOhd (Heilscher, 
Germany) with titanium sonotron was used at a power of 15 W/cm During the 
experiments, the temperature was controlled at 25-30 °C 
Surface potential (zeta potential) and particle size measurements (by light 
scattering) were performed using ZetaPlus microelectrophoresis (Brookhaven 
Instruments, Co ) Additionally, we used Precision detectors PDExpert light scattenng 
Workstation to check the radius of gyration of our drug nanoparticles A field emission 
scanning electron microscope (Hitachi S 4800) was used for particle imaging XRD 
experiments were performed with the help of a Bruker D8 Discover X-ray Diffracto-
meter to determine the crystalline structure of drug nanoparticles 
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The drug release rates of nanocapsules with different shell composition were 
measured using standard 1 mL horizontal diffusion chambers with 0 2 um cellulose 
acetate membranes The drug dispersion was placed to the side of the diffusion chamber 
contaimng a magnetic stmer and the drug was released against the same volume of 
PBS, pH 7 2 to mimic the sink conditions expected in vivo The concentration of 
released drugs in PBS was dissolved in ethanol at 1 1 (v/v), centnfuged to remove 
insoluble polyelectrolytes and measured with a UV spectrophotometer (Agilent 8453 
Wavelength range 190-1100 nm) Curcumin was measured at 490 nm, and pachtaxel 
was measured at 245 nm Also the same measurements were done to calculate product 
yield at the end of somcation Further, we describe the instruments used in this work in 
more detail 
3 1 Ultrasonicator 
A Hielscher UlPlOOOhd ultrasonic processor, Figure 3-1, was used to prepare 
nanoparticles in this research 
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Figure 3-1 Hielscher UlPlOOOhd ultrasomc processor 
When ultrasomc energy is applied to liquids, and if amplitude and acceleration 
are high enough, the phenomenon of cavitation occurs The cross-section of sonotnn 
used conesponded to the surface area of the drug dispersion to maximize 
ultrasonication power The liquid bursts and vacuum bubbles are generated during the 
alternating high-pressure and low-pressure cycles When these small bubbles cannot 
absorb more energy, they implode during a high-pressure cycle, so pressures up to 
1,000 bar and shock waves as well as liquid jets of up to 400 km/h are reached locally 
These intense forces, caused by ultrasonic cavitation, take effect on the enclosing 
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droplets and particles The main objective of power ultrasonics consists of cavitational 
forces, with heating being mostly a welcome side-effect Cavitation and the effects 
descnbed above cause mterparticle collision 
3.2 Zeta Potential Analyzer 
A ZetaPlus zeta potential analyzer (Brookhaven Instruments, Co ), Figure 3-2, 
was used to measure the surface charge of nanoparticles dunng the LbL assembly 
process This instrument also can be used to measure the particles hydrodynamic 
diameter using light scattering 
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Figure 3-2 Zeta potential analyzer by Brookhaven Instruments, Co. 
Zeta potential meassurement was calibrated using a BI-ZR3 zeta potential 
reference material provided by Brookhaven Instruments, Co. 
100 mg of BI-ZR3 was added to 20 mL of the 1 mM KC1, result in 5mg/mL 
concentrate. Then the concentrate dilutes to 1.25X102 mg/mL. This standard sample is 
used to have a mean zeta potential value of 53 mv ± 4 mv, and 300 nm mean size. 
Zeta potential is used as a surrogate for surface change and is often measured by 
observing the oscillations in signals that result from light scattered by particles located 
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in an electnc field, though there are other approaches There are a number of 
instrumental configurations by which this is achieved, mostly using a doppler shift, and 
the users should familiarize themselves with the particular approach implemented in 
their equipment Instrumentation concerns aside, the need for dilution begs the question 
of what is an appropnate diluents, because its choice can profoundly influence the 
surface chemistry and thus the results This analyzer was calibrated using a BI-ZR3 
reference matenal from Brookhaven Instruments, Co 
3.3 Dynamic Light Scattering 
The Precision detectors PDExpert light scattering workstation Figure 3-3 is a 
multi-detector light scattering platform that can be employed for light scattenng 
measurements on a static sample (eg a test tube) or for flow through measurements 
(e g high performance liquid chromatography, gel permeation chromatography and size 
exclusion chromatography) The workstation is designed to provide the ultimate in 
detection for characterization of polymers, nanoparticles, lipids, colloids and proteins 
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Figure 3-3 Precision detectors PDExpert light acattering 
workstation 
DLS, also known as photon correlation spectroscopy (PCS) or quasi-elastic light 
scattering (QELS) records the variation in the intensity of scattered light on the 
microsecond time scale. This variation results from interference of light scattered by 
individual particles under the influence of Brownian motion, and is quantified by 
compilation of an autoconelation function. This function is fit to an exponential, or 
some combination or modification thereof, with the conesponding decay constants 
being related to the diffusion coefficients. Using standard assumptions of spherical size, 
low concentration, and known viscosity of the suspending medium, particle size is 
calculated from this coefficient. The advantages of the method are the speed of analysis, 
lack of required calibration, and sensitivity to submicrometer particles. Drawbacks 
include the necessity of significant dilution to avoid artifacts, the need for cleanliness in 
sample preparation, the mathematical instability of the procedure used to extract decay 
constants, and the possible influence of interparticle interactions. DLS is a stand-by 
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method for those working in the area of nanoparticles because of the simple measure 
3.4 X-Rav Diffractometer 
A Bruker D8 X-Ray diffractometer was used to determine the crystal structure 
of the nanoparticles (Figure 3-4) 
Figure 3-4 Bruker D8 Discover X-ray diffractometer 
3.5 SEM 
Figure 3-5 shows the Hitachi SEM which was used for nanoparticles 
visualization Diluted drug nanoparticles dispersion was dropped on a suitable substrate 
and coated with a ca 0 5 nm gold layer to provide conductivity 
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Figure 3-5 Hitachi S-4800 scanning electro microscope 
This SEM also has an energy-dispersive X-ray spectroscopy (EDX) detector 
(EDAX Sapphire). EDX Analysis can be used to determine the element composition of 
the sample. 
3.6 Ultra Violet Spectrophotometer 
An UV-vis spectrophotometer (Agilent 8453), Figure 3-6, was used to measure 
the concentration of drug in the release test. The drug release test measures the 
pharmacodynamic diffusion of the nano drug particle in a side-by-side diffusion 
chamber. 
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Figure 3-6 Agilent 8453 UV-Vis spectrophotometer 
CHAPTER 4 
DRUG NANOPARTICULATION VIA TOP-DOWN APPROACH 
Nanoparticle drug earners were developed using a combination of 
ultrasonication and encapsulation with synthetic and biodegradable polyelectrolytes 
Two different approaches to attain the desired featured properties are the "top-down" 
and "bottom-up" synthetic methods These two methods are desenbed in Chapters 4 and 
5 A common feature of these two related methods is ultrasonication-driven formation 
of drug nanocores accompanied by a simultaneous polycation coating providing 
aqueous colloidal stability The "top-down" method was more efficient in the 
preparation of large amounts of 200-250 nm diameter pachtaxel capsules, and the 
"bottom-up" approach allowed for the formation of smaller capsules of ca 100 nm 
diameter but with less product yield Some sections of these two chapters were 
published in papers written by the author of this dissertation and will be 
conespondingly refened [148] and [149] 
4.1 Methodology 
Powerful ultrasound generates micro-bubbles in a liquid These micro-bubbles 
collapse in microseconds If any solid particle is near the bubble dunng the collapsing, 
jets of fluid and shock waves will hit the particle and break it up While adding 
polyelectrolyte into the solution, the typically negative surface of the newly formed 
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drug surface will help to keep particles from aggregation Thus, a smaller particle size 
can be achieved with a better size distribution Because the ultrasonication process 
breaks down the particles, it is a mechanical process The formed particles will have a 
wide range of sizes Both power and somcation time effect the nanoparticles' size 
distnbution In general, the higher the power and the longer the time, the smaller the 
particles will be But if one stops somcation, particles will aggregate To prevent the 
aggregation during the somcation and increase the efficiency of the somcation, we 
added polycations that adsorbs onto the drug nanoparticles and prevents re-aggregation 
The mimmum amount of polycation needed for complete coverage was calculated in 
Appendix A The surface zeta potential of the particles changed to positive during the 
polycation adsorption and reached of ca + 40mV 
For drug encapsulation, anionic sodium polystyrene sulfonate (PSS) of MW 70 
KDa and catiomc poly(dimethyldiallyl ammonium chlonde) (PDDA) of MW 100 KDa 
were sequentially adsorbed onto the particles of different drugs at pH 6, and then the 
desired number of layers in the capsule shell was fabncated Biodegradable 
polyelectrolytes that were used for the LbL assembly are protamine sulfate and 
chondroitin sulfate The multilayer shells that are fabncated on the drug help in 
prolonging the release of the drug Figure 4-1 shows the scheme for top-down approach 
The verification of the alternation of surface charges and particle size were done with a 
ZetaPLus Brookheaven microelectrophoretic zeta-potentiometer A visualization of the 
fabncated microcapsules was completed using SEM 
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LbL assembly on to particle 
Figure 4-1 Scheme for top-down approach 
4.2 Curcumin Nanoformulation 
Curcumin is a well known natural compound traditionally used as a food 
additive or a health nutrient supplement in many oriental countries Recently, its anti-
cancer activity was recognized [150] It is a low soluble compound (the aqueous 
solubility is ca 0 01 mg/mL) The curcumin structural formula is shown in Figure 4-2 
OH 
O O 
Figure 4-2 Structural formula for curcumin 
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4.2.1 Preparation of curcumin nanoparticles 
The following expenmental step-by-step sequence was used to prepare 
nanoparticles of curcumin 
1) 10 mg curcumin powder was mixed with 10 ml of DI water 
2) The mixture was pre-somcated for 5 mm to form curcumin suspension 
3) 2 mL of 1 5 mg/mL catiomc PAH were added to the suspension 
4) 45 mm somcation was applied 
5) The curcumin nanoparticles were washed twice with DI water using 
centnfugation at 7000 rpm (5204 g rcf) for 10 min to separated 
nanoparticles from supernatant and re-dispersed in 20 mL of DI water 
6) 2 mL of 3 mg/mL anionic PSS were added to the mixture, 10 mm of 
reaction time was allowed for the polyelectrolyte adsorption 
7) The supernatant was removed by centnfugation at 7000 rpm 
Nanoparticles were washed with DI water and re-dispersed 
8) Steps 6-7 were repeated for next layer of catiomc PAH 
9) Steps 6-8 were repeated several times to achieve the desired number of 
polyelectrolyte layers in the coating 
Instead of catiomc PAH and anionic PSS, biodegradable polyelectrolytes such 
as protamine sulfate (PS), bovine serum albumin (BSA) and chondroitin sulfate (ChS), 
may be used for the coating 
The alternation of electrophoretic (£) potential demonstrates a step-wise 
formation of the LbL-shell consisting of catiomc PAH and aniomc PSS on curcumin 
nanoparticles Figure 4-3 shows a typical zeta potential change dunng the ultrsonic 
assisted LbL assembly process Each sample was measured 10 times The standard 
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deviation was given by the zeta potential analyzer After the initial -50 ± 2 mV for bare 
curcumin particles, PAH adsorption during the first step of nanoparticles synthesis 
converts the potential to +30 ± 2 mV Next, anionic PSS adsorption changes the 
potential to -53 ± 2 mV, followed by +20 ± 2 mV with PAH, and again -50 ± 2 mV with 
PSS Therefore, a multilayer coating of polycations and polyamons with composition of 
(PAH/PSS)2 was coated onto the curcumin nanoparticles and the enhanced surface 
potential of -50 mV was reached This value is well above commonly accepted colloidal 
stability threshold of (±) 30 mV [149] 
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Figure 4-3 ^-potential alternation during LbL-shell formation of 
catiomc PAH and anionic PSS on curcumin 
nanoparticles Standard deviation shows the same 
sample run 10 times on zeta potential analyzer 
Separate QCM analysis of the LbL assembly process for these polyelectrolytes 
on silver plated 9-MHz Quartz Crystal Microbalance resonators (USI-System Instr, 
Japan) demonstrated a thickness increment of 2 0 ± 0 3 nm for a PAH/PSS bilayer, and 
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the total thickness of the two-bilayer shell on the curcumin nanoparticles may be 
estimated as ca. 4 nm. Any shell composition may be achieved with further alternate 
adsorption of polycations and polyanions [149]. 
In another experiment, curcumin nanocapsules with two bilayer shells of 
biocompatible protein materials were produced. A positive layer in the shell was 
generated using protamine sulfate (PS), while bovine serum albumin (BSA) formed a 
negative layer. Total composition produced was (PS/BSA)2. For these LbL 
nanocapsules, zeta potential also regularly alternates between +30 mV and -50 mV 
providing high colloidal stability of the samples [149]. The dispersion of the 
nanoparticles with the concentration of 0.2 g/mL was stored in DI water for two weeks 
without precipitation. 
The yield of the nanoparticles was about 30-40 % which means that, if curcumin 
concentration at the beginning of the process was typically 1 mg/mL, then, in the 
product, it was of about 0.3-0.4 mg/mL. 
Figure 4-4 shows SEM image of the formed curcumin nanoparticles. One can 
see that, in diluted dispersions, the nanoparticles' size is from 50-120 nm (left) and, 
upon the drying of the concentrated sample, some aggregation occurs (right image). 
Figure 4-4 SEM image of the formed curcumin nanoparticles (left) 
diluted sample, and (right) concentrated sample 
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4.3 Nanoformulation of Pachtaxel 
Pachtaxel (Figure 4-5) is an efficient anti-cancer drug, but due to very low 
solubility, there is not effective way for its delivery However, with pachtaxel 
nanoformulation it is feasible to increase the drug concentration a hundred times (up to 
a few mg/mL) 
Figure 4-5 Structural formula for pachtaxel 
Figure 4-6 shows a typical zeta potential change during the assembly Each 
sample was measured 10 times The standard deviation was given by the zeta potential 
analyzer One can see the zeta potential changes for the LbL assembly of 
polyelectrolyte multilayer shell on pachtaxel nanoparticles Imtially, the surface 
potential of the pachtaxel nanoparticles was -21 mV After deposition of the first 
catiomc PAH layer (with simultaneous ultrasomcation) we obtained the particle surface 
potential of 24 ± 3 mV After deposition of the second layer, anionic polyelectrolyte 
layer (PSS), we increased the magnitude of zeta potential to 41 ± 3 mV, and finally, at 
the last deposition step a coating with biodegradable chitosan/algmic acid (blue line) or 
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albumin (red line) gave us a strong negative surface charge of the encapsulated 
pachtaxel of - 46 ± 4 mV and -32 ± 3 mV This high surface potential provided for the 
stability of the developed pachtaxel nanocoUoids for at least two weeks at 
concentrations of 0 5 mg/mL 
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Figure 4-6 ^-potential of pachtaxel coated with two different 
bilayers of PAH-PSS-PAH-BSA and PAH-PSS-
chitosan-algmic acid (using top-down approach) 
Standard deviation shows the same sample run 10 times 
on zeta potential analyzer 
In Figure 4-7, one can see the SEM image of the initial micromzed sample of 
pachtaxel It consists of needle-like rods with diameter of ca 100 nm and length of 2-3 
um Dunng sonication-assisted LbL encapsulation, we obtained rather homogeneous 
particles with overage sizes of 100 x 100 x 200 nm This particle suspension is 
collapsed dunng the drying of the sample but the aqueous dispersion itself is stable It is 
interesting, that due to very low solubility, it is possible to keep the pachtaxel sample 
without dissolution for weeks because in such a restncted volume the supernatant 
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saturation is reached preventing further particles dissolution. Only in a big solvent 
volume (under sink release conditions), can pachtaxel nanoparticles be partially or 
completely dissolved. These particles are less than 300 nm and are in accordance with 
the minimum particle size allowed by FDA for medical injections. 
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Figure 4-7 SEM image of orginal pachtaxel (left) and after 
ultrasound assisted LbL encapsulation with 
PAH/PSS/chitosan/alginic acid (right) 
CHAPTER 5 
DRUG NANOPARTICULATION VIA BOTTOM-UP APPROACH 
This technology is our new invention It was disclosed to LaTech 1) Z Zheng, 
Y Lvov "Somcation synthesis of polyelectrolyte coated nanoparticles through mixing 
molecular solutions with bad solvents," September 30, 2008-27, and 2) Y Lvov, Z 
Zheng, V Torchihn "Pachtaxel and atavoquone nanoparticle production through 
ultrasonication with gradual desolvation assisted with polycation coating Synthesis of 
the mixed drugs nanoparticles," December 1, 2008-30 US patent application by V 
Torchihn, Y Lvov, Z Zheng "Stable Aqueous NanocoUoids of Pachtaxel and 
Atavoquone," was filed by Louisiana Tech University and Northeastern University on 
April 25, 2009 Some sections of this chapter were published in a paper written by the 
author of this dissertation and will be conespondmgly refened [149] Z Zheng, X 
Zhang, D Carbo, C Clark, C-A Nathan, Y Lvov, Langmmr, v 26, 7679-7681, 2010 
"Somcation assisted synthesis of polyelectrolyte coated curcumin nanoparticles " 
5.1 Methodology 
The drug powder was dissolved in ethanol/water solution After drug has been 
completely dissolved, we added aqueous polycations, poly(allylamme hydrochlonde) 
(PAH) or biodegradable protomme sulfate (PS), and started ultrasonication with a 
UIPIOOO, Hielscher instrument, at energy density of 100 Wt per mL of solution During 
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the somcation, water was slowly added into the solution Because of the added water, 
the solvent becomes more polar, causing a decrease of drug solubility, and eventually, 
its concentration exceeds the solubility threshold resulting in the drug supersaturated 
conditions Then, crystal nucleation starts Under high power ultrasonication, the drug 
particle growth ceases at the initial stages [149] An adsorption of polyelectrolytes onto 
the drug nanocrystals establishes a barner for their further growth and aggregation The 
minimum amount of polyelectrolytes needed for complete coverage was calculated in 
Appendix A Obtained drug crystal particles were stable and did not aggregated after 
somcation was stopped We assume that it was because of the increase of surface charge 
provided by the adsorbed polyelectrolyte layer After 45 min of somcation, drug 
nanocrystals were separated from the solution by centnfugation and re-suspended in DI 
water Additional polyelectrolyte multilayers were built on the curcumm nanoparticles 
by alternate adsorption of polyamons and polycations (LbL shell assembly) For 
biocompatible capsules, an alternate adsorption of catiomc protamine sulfate (PS) and 
anionic bovine serum albumin (BSA) were used (Figure 5-1) 
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Figure 5-1 Scheme of the bottom-up curcumin LbL 
nanoformulation 
The drug was dissolved in 60 % ethanol at a concentration of 2 mg/mL We 
present here the results for low solubility anti-cancer drugs curcumin and pachtaxel 
Ultrasonication was applied for 45 min while slowly adding water at the rate of 0 2 
mL/min [149] 
5.2 Curcumin Nanoformulation 
5.2.1 Nanocurcumm preparation 
The drug/shell multilayer structure is curcumin/PS/BSA/PS/BSA 
The following expenmental step-by-step sequence was used to prepare 
nanoparticles of curcumin 
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1) 10 mg curcumin were dissolved in 10 ml of 60 % ethanol/water 
(optionally, we also used acetone) 
2) The solution was presomcated for 5 mm to completely dissolve the 
curcumin 
3) 6 mL of 0 2 mg/mL aqueous catiomc PS, pH 6 5 were slowly added at a 
speed of 0 5 mL/min during 30 mm somcation This is the key step of the 
procedure initiating the particle nucleation 
4) The nanoparticles were washed twice with DI water using 7000 rpm 
centnfugation to separate the nanoparticles from supernatant 
5) 3 mg of aniomc BSA were added to the mixture and allowed to adsorb for 
10 min 
6) The nanoparticles were washed twice with DI water using 7000 rpm 
centnfugation before coating with aqueous cationic PS 
7) 3 mg of PS were added to the mixture and allowed to adsorb for 10 min 
8) Steps 4-7 were repeated to achieve a given number of layers 
Figure 5-2 shows a typical zeta potential change during the ultrsonic assisted 
LbL assembly process Each sample was measured 10 times The standard deviation 
was given by the zeta potential analyzer Due to the adsorption of cationic PAH, the 
surface potential of these nanoparticles was positive ca +30 mV Further coating with 
PSS increased the zeta potential magmtude to -52 ± 4 mV High surface charge 
increases colloidal stability for this formulation For example, in an aqueous curcumin 
nanocolloid of 0 5 mg/mL concentration a stable dispersion of the drug was preserved 
for one month In Appendix B, we calculated the average distance between particles 
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under different conditions Low concentration means longer distance between particles, 
which usually means better stability 
40 -1 
30 -
^ 20 -
3 10 -
2 -io -
1 -20 -
<£ -30 -
5 -40 -
M
 -50 -
-60 -
i u 
SPAH 
/ \ APAH 
* curcumin \J 
$PSS 
Adsorbed polylectrolyte 
*PSS 
Figure 5-2 Particle ^-potential alternation dunng LbL coating of 
curcumin (pH 6 5) Standard deviation shows the same 
sample run 10 times on zeta potential analyzer 
Curcumin nanoparticles of rectangular shape were obtained Edges from 60 nm 
to 90 nm (Figure 5-3) and average edge size of 80 ± 20 nm were estimated with SEM 
imaging processing software Quartz PCI (Hitachi) and light scattenng experiments 
(Brookhaven Instruments, Co , ZetaPlus) The rectangular shape of the nanoparticles is 
associated with the crystalline nature of the obtained curcumin particles [149] 
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Figure 5-3 SEM images of initial curcumin powder (left) and 
resulting curcumin nanocolloid (right) 
To examine the crystal structure of the curcumin nanoparticles, X-ray powder 
diffraction analysis was carried out with a Bruker-D8 XRD instrument. Bragg peak 
positions in the X-ray pattern obtained from the dried nanoparticles powder coincided 
with the peak positions for bulk curcumin powder, but the peaks were wider due to 
smaller crystallite size (Figure 5-4). These X-ray data indicate that the crystal structure 
of curcumin was preserved, and polycations added during drug crystal formation did not 
form a complex with curcumin molecules but only covered the crystals surface. We 
assume that polycations were layered predominantly on the crystal surface, as it follows 
from electrophoretic (^-potential) data given below [149]. 
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Figure 5-4 X-ray diffraction spectra for micromzed curcumm 
powder (upper spectrum) and for nanoformulated 
curcumin (lower spectrum) 
5 3 Pachtaxel Nanoformulation 
5.3.1 Preparation of nanopachtaxel 
The following experimental step-by-step sequence was used to prepare 
nanoparticles of pachtaxel 
1) 10 mg of pachtaxel were dissolved in 10 mL of 60 % ethanol/water 
solvent 
2) The mixture was presomcated for 5 mm to completely dissolve pachtaxel 
3) 6 mL of aqueous 0 2 mg/mL cationic PS (pH 6 5) was added at a speed of 
0 5 mL/min dunng 45 mm somcation This is the most important stage of 
the formulation 
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4) The nanoparticles were separated from supernatant using 7000 rpm 
centnfugation for 10 min and washed twice with DI water Then the 
nanoparticles were redispersed in 10 ml of DI water 
5) For next BSA layer, 3 mg BSA were admixed to the dispersion for 10 min 
6) Step 4 was repeated 
7) A layer of catiomc protamine sulfate was deposited in the same way as in 
step 5 
8) Step 4 was repeated 
9) Steps 5-8 were repeated to obtain the desired coating structure 
Pachtaxel was dissolved in a "good" solvent (60 % ethanol/water or 60 % 
acetone/water) After dissolution of the drug at high concentration, ultrasonication was 
started with aqueous polycation slowly added to the solution With an increase of water 
concentration, solubility of pachtaxel decreased, reached saturation and the nucleation 
began resulting in the formation of nano-size particles 
Powerful somcation prevents formation of larger drug particles and polycation 
adsorption provides for a surface charge sufficient for colloidal stability After a 45 min 
treatment, the drug particles were centnfuged at 7,000 rpm for 10 mm and re-suspended 
in distilled water The second layer of anionic polyelectrolytes was deposited to 
maximize the capsule surface potential Nonreacted polyanions were removed by 
centnfugation and pachtaxel nanoparticles with the average particle size of 100 nm 
were obtained Additional polyelectrolyte layers may be further built up on the drug 
nanoparticles using the traditional LbL process without somcation Obtained pachtaxel 
nanocolloid was kept in a small volume of saturated solution to prevent drug release 
[149] 
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Figure 5-5 shows a typical zeta potential change dunng the Ultrsonic assisted 
layer-by-layer assembly process Each sample was measured 10 times The standard 
deviation was given by the ZetaPlus zeta potential analyzer (Brookhaven Instruments, 
Co) The alternated zeta potential dunng formation of LbL nanoshells on pachtaxel 
nanocores has a minimal potential of-35 mV 
50-
40-
30-
s 20 ' 
£ 10-
? < o- -10 -
N .20 • 
-30 -
40 -
50 -
i 1 / 
Pacta xel(1mg) 
Paclitotel (PS BSA 
* PS) 
I Paclfcwel (PS) / \ 
2 \ 3 / 4 \ 5 6 
Pacllaxel(PS BSA) V 
Paclnaxel (PS BSA)2 
Adsorbtion Cycle 
Figure 5-5 ^.-potential change dunng the LbL encapsulation of 
pachtaxel Standard deviation shows the same sample 
run 10 times on zeta potential analyzer 
Figure 5-6 shows SEM image of the resulting nanocapsules with average 
diameter of 90 ± 20 nm 
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Figure 5-6 SEM image of pachtaxel nanoparticles with shells of 
(PS/PSA)2 (left); same sample showing aggregation of 
particles at another site (right) 
Figures 5-7 shows the SEM images of pachtaxel particles prepared with the 
bottom-up approach, then using centrifuge to separate large particles and small 
particles. 
Figure 5-7 SEM image of pachtaxel in 60 % ethanol sonicate for 
45 min before (left) and after (right) centrifuge 
CHAPTER 6 
PROCESS OPTIMIZATION 
6.1 Ultrasonication Time 
The first parameter we optimized was somcation time It is logical to assume 
that the longer the somcation, the smaller particles one can get However, in the "top-
down" approach, even many hours of somcation did not result in particles less than 200 
nm Probably, there is a limitation preventing further splitting of the drug particles In 
ref [151], it was suggested that this minimal size may be related to the nucleation size 
of vapor bubbles during somcation The only imporvement which we suggest m future 
work could be a modification of the cavitation process in somcation by changing 
solution properties and vapor bubble formation conditions (for example, with increased 
pressure) Finally, the optimized somcation time for the nanoformulation of curcumin 
and pachtaxel was chosen to be 30-45 min Another factor, requinng the limitation of 
somcation time is sample pollution with depleted submicron particles of titanium oxide 
This pollution is developing with somcation times above one hour and then additional 
sample punfication to eliminate titanium alloy particles is needed Fortunately, it is 
relatively easy due to different particle densities As shown in Figure 6-1, the particle 
size decreases when the somcation time increase The result was achieved after seven 
measurements at each data point The standard deviation was given by the 90Plus 
particle sizer 
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Figure 6-1 Decrease of curcumin nanoparticles size as a function of 
somcation time in the presence of polycation Standard 
deviation shows the same sample run seven times on 
90Plus particle sizer 
6.2 Water Add-m Speed and Drug Concentration 
To minimize the curcumin particle size, we prepared a series of samples 
processed under vanous conditions (different ethanol/water ratios, drug concentrations, 
ultrasonication power, time, and speed of the solvent worsening for crystallization 
initiation) Two major factors that affect the crystal size were the rate of water addition 
(speed of the solvent worsemng) and an initial curcumin concentration These factors 
were optimized Figure 6-2 gives the dependence of particle size on the rate of water 
addition The result was achieved after seven measurements at each data point The 
standard deviation shows the same sample run seven times on 90Plus particle sizer 
(Brookhaven Instruments, Co) 
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Figure 6-2 Dependence of curcumin particle size on water addition 
rate Standard deviation shows the same sample run 
seven times on 90Plus particle sizer 
The water addition rate was varied from 0 05 mL/min up to 0 4 mL/mm for the 
sample volume of 50 mL, and the higher rate resulted in the formation of larger 
particles We observed particles of ca 320 nm average size at 0 4 mL/mm rate versus 
ca 120 nm particles for the 0 05 mL/min rate 
An increase of curcumm concentration in the initial solution also resulted in 
larger nanoparticles as shown in Figure 6-3 The result was achieved after seven 
measurements at each data point The standard deviation shows the same sample run 
seven times on 90Plus particle sizer (Brookhaven Instruments, Co) Slightly larger 
sizes of curcumin nanoparticles, as obtained with the light scattering technique (ca 100 
nm) as compared with mean 80 nm size average over thirty particles in the SEM image 
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may be explained by the fact that light scattenng is more sensitive to the admixture of 
larger particles in the sample, which were excluded in the SEM estimations [149] 
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Figure 6-3 Dependence of curcumin particle size on curcumin 
concentration Standard deviation shows the same 
sample run seven times on 90Plus particle sizer 
CHAPTER 7 
DRUG RELEASE 
We use a set of side-by-side diffusion cells (PermeGear, Inc) to measure the 
drug release profile 
The setup is shown in Figure 7-1 We use a 0 1 urn membrane to separate the 
two chambers The joint between the sections was sealed with silicone gel We fill the 
receptor chamber with DI water and fill the donor chamber with the drug sample and 
start timing After a certain time penod we take out all the solution in the receptor 
chamber and refill it with DI water again Each solution that is taken out from the 
receptor chamber is labeled (si, s2, s(n-l)) then measured for drug concentration 
with UV spectrophotometer (Agilent 8453) A standard curve is measured earlier to 
establish the relationship between concentration and absorption, and a linear 
relationship was found At the end of the release test, both solutions from the receptor 
chamber (sn) and the donor chamber (sd) were taken out and measured for 
concentration The release rate was established by accumulating the amount of the drug 
taken out from the receptor at time x 
Total amount of drug =S 1+S2+ +Sn+Sd 
Release rate at time x= (S1+S2 +Sx) / Total amount of drug 
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Figure 7-1 Release test side-by-side diffusion cell set up (Scheme 
of side-by-side cells kindly provided by PermeGear, Inc ) 
7 1 Curcumin Release from Nanocapsules 
The drug release profile of the curcumin LbL-nanocolloids with the (PS/BSA)2 
coating was analyzed in a diffusion chamber (sink conditions) (Figure 7-2) 50 % drug 
release from LbL coated nanoparticles was reached in seven hours and 60 % release 
was reached withm ca 20 hours This release is slower than for nano-curcumin powder 
without the LbL shell or the original micromzed curcumin We have to emphasize that 
the main goal of our work is not slowing down of the drug release rate but the 
formulation of stable drug nanocoUoids with injectable particle size (below 300 nm) 
However, a slower release time is useful and is an indirect proof of the shell formation 
providing a diffusion bamer for the particles and slowing down their dissolution 
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Figure 7-2 Release profiles of curcumin in ongmal micropowder 
form, after nanoparticulation and prepared with LbL 
nano-encapsulation (the shell composition (PS/BSA)2) 
The release profile fits the Peppas model M,/Mx = Kt" , where M, is the 
amount of drug released at time t, Mm is the amount of drug released at infinite time, n 
is the exponent charactenstic of the release mechamsm, and K is a constant Detail of 
the fitting can be seen in Appendix C The obtained value for n less than 0 5 indicates 
that the release mechamsm is Fickian diffusion 
7.2 Pachtaxel Release from Nanocapsules 
The release profiles of the onginal pachtaxel powder, pachtaxel nanocoUoids 
with one polycation layer and three polycation/polyamon bilayer coating were analyzed 
64 
in standard sink conditions The fitting of the release curves were accomplished with 
exponential Peppas' model Withm eight hours, 70 % of onginal pachtaxel powder was 
released (Figure 7-3) 
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Figure 7-3 Release curves for the original micronized powder of 
pachtaxel, uncoated pachtaxel nanoparticles (only one 
PAH layer adsorbed for colloidal stabilization) and 
nano-encapsulated pachtaxel with (PAH/BSA)2 shell 
composition 
Nanoparticulated pachtaxel coated with one polyelectrolyte layer leads to 
slightly faster release due to a smaller particle size in nanoformulation, as compared 
with the micrometer size of the original pachtaxel Pachtaxel nanocoUoids, coated with 
two bilayers of PAH/BSA, showed a lower drug release rate due to the increasing 
thickness of the capsule wall For example, in eight hours, only 40 % of the two layers 
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coated sample was released as compared with 80 % for the one layer coated sample 
The LbL encapsulation technique allows for control of the drug release rate from 
polyelectrolytes-stabihzed nanoparticles by changes in the number of coating layers or 
the shell composition [148] 
CHAPTER 8 
CONCLUSIONS 
Two methods (top-down and bottom-up) of nanoparticle formulation for low 
water-solubility materials were developed and applied for nanoformulation of anti-
cancer drugs curcumin and pachtaxel The resulting drug nanoparticles have a diameter 
of 100-220 nm and are stable in water 
In the first, top-down method, the drug powder was broken up by ultrasound 
through the collapse of microbubbles (with jet fluid and shock waves) By adding 
polycations into the solution, the slightly oxidized negative surface of the newly formed 
particles was recharged positively to a higher surface potential which prevented 
particles from aggregating This approach was proposed earlier, and we applied it to the 
new drugs pachtaxel and curcumin, the resulting nanoformulated drug had diameters of 
ca 200-250 nm 
In this work we pioneered the second bottom-up nanoformulation method The 
drag was dissolved m an organic solvent that is miscible with water (ethanol or acetone) 
and its nucleation was initiated by the gradual decrease in the solubility of the solution 
with addition of aqueous polyelectrolyte The process was assisted by ultrasonication 
Similarly to the first method, the polyelectrolytes coating induced higher surface charge 
on the formed nanoparticles and provides nanocolloid stability This coating was 
extended to achieve multilayer encapsulation through alternate adsorption of oppositely 
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charged synthetic and biodegradable polyelectrolytes (polyallyl amine, sodium 
polystyrenesulfonate, chitosan, bovine serum albumin, protamine sulfate, and alginic 
acid) Unlike the commonly used emulsion methods, our ultrasonication assisted layer-
by-layer nano-encapsulation method allowed for achieving nanoparticles of a much 
smaller size We obtained crystalline nanoparticles with an average size of 80 nm, and 
zeta potential of+30 mV or -50 mV (depending on the number of polyelectrolyte layers 
in the shell), which ensured the stability of the nanocoUoids in water for weeks at a 
concentration of ca 0 2 mg/mL Formation of shells with two bilayers of biocompatible 
polyelectrolytes allowed for slow drug release during ca 20 hours 
The product efficiency of the top-down approach was ca 50 %, which was 
higher than the efficiency of the bottom-up approach (ca 20 %) The bottom-up 
approach leads to increased losses due to the formation of larger particles at a fast 
nucleation rate Larger were removed by centnfugation thus decreasing the yield of the 
nanoparticles final product 
Ultrasound assisted layer-by-layer nano-encapsulation is a promising technique 
to produce stable 1-2 mg/mL concentration nanocoUoids of poor water soluble drugs, 
like pachtaxel, curcumin, and others The particle size in such drag formulation is 
reduced from the initial tens of micrometers m the drag powders to 100-200 nm which 
allow climcal injection Nanoparticle coating with natural polyelectrolytes 
(polysaccharides) has the potential to increase drag circulation time and availability at a 
rumor site Layer-by-layer encapsulation was earned out with biodegradable 
polyelectrolytes protamine sulfate, alginic acid, chitosan and bovine serum albumin 
The drag particle size can be optimized using either top-down or bottom-up sonicated 
LbL-treatment 
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Future work 
The stability of nanocoUoids at a concentration of 2 mg/mL in buffers with 0 1 
M salt concentration needs to be improved Our formulation allowed stable 
nanocoUoids only in solutions with low salt concentrations The free reactive groups of 
biocompatible polyelectrolytes (amine or acidic) at the outermost layer may help to bind 
PEG for longer particle circulation in blood or receptors for targeted drag delivery 
Further process improvement of both top-down and bottom-up techniques can 
be achieved by increasing the somcation power Ultrasonication efficiency depends on 
the shock wave power released on the drag particle surface due to the collapsing of gas 
microbubbles One can choose additives which will increase the number of bubbles and 
decompose without damaging the original drug product Another approach to increase 
somcation power is working under elevated pressure, which may be reached using a 
compressed gas atmosphere New graduate students will work on constructing a high 
gas pressure chamber for ultrasonication 
For drag nanoparticles targeting, we are planning to use a chemically active 
layer (with acidic, amine groups) as the outside LbL coating layer to link antibody to 
target drugs to specific cancer cells 
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To estimate the minimum amount of polyelectrolyte needed for complete 
coverage of nanoparticles we perform the calculation m Table A-1 In this case we 
calculate the PAH needed to complete coat 2 g of pachtaxel which have a rectangular 
sharp and average edge of 300 nm length 
Table A-1 Minimum amount of polyelectrolyte needed for coating 
Assume PTX density= 
PTX weight 
average single PTX size 
average single PTX size nm 
volume of PTX=w/p 
single PTX volume 
number of PTX particle 
single PTX surface 
total surface 
thickness of PAH 
thickness of PAH nm 
volume of PAH 
PAH density 
PAH weight 
PAH weight in mg 
1 5 
2 00E-02 
3 00E-05 
3 00E+02 
1 3333E-02 
2 70E-14 
4 9383E+11 
5 40E-09 
2 6667E+03 
2 00E-07 
2 00E+00 
5 3333E-04 
1 6 
8 5333E-04 
8 5333E-01 
g/cm 
g 
cm 
nm 
cm3 
cm3 
cm 
2 
cm 
cm 
nm 
cm3 
g/cm 
g 
mg 
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We found that the stability of drag nano colloid was effect by the concentration 
of the colloid In general, we found the lower the concentration the better the stability 
To estimate the average distance between particles at a certain concentration, we prefer 
the calculation in Table B-1 (for sphere sharp) and Table B-2 (for cube sharp) 
Table B-1 Average distance between sphere particles 
Calculate particle as sphere 
Weight of drug in 1ml solution(mg) 
Density of drug (mg/ml) 
Weight of water (mg) 
Concentration (mg/ml) 
Size of particles (nm) 
Size of particles (cm) 
Weight of each particle (mg) 
Number of particles 
Volume of each particle (round) (ml) 
Volume of solution outside a 
Volume of each cell (ml) 
Distantce cm 
Distantce um 
particle(ml) 
Sample 1 
05 
1500 
1000 
05 
200 
0 00002 
6 28E-12 
7 96E+10 
4 19E-15 
1 26E-11 
126E-11 
0 000232 
2 324897 
Sample 2 
2 
1500 
1000 
2 
200 
0 00002 
6 28E-12 
3 18E+11 
4 19E-15 
3 14E-12 
3 15E-12 
0 000146 
1 464593 
Sample 3 
5 
1500 
1000 
5 
200 
0 O0002 
6 28E-12 
7 96E+11 
4 19E-15 
1 26E-12 
1 26E-12 
0 000108 
1 079121 
Table B-2 Average distance between cube particles 
Calculate particle as cube 
Weight of drug in 1ml solution(mg) 
Density of drag (mg/ml) 
Weight of water (mg) 
Concentration (mg/ml) 
Size of particles (nm) 
Size of particles (cm) 
Weight of each particle (mg) 
Number of particles 
Volume of each particle (cube) (ml) 
Volume of solution outside a particle (ml) 
Volum of each cell (ml) 
Distantce cm 
Distantce um 
Sample 1 
05 
1500 
1000 
05 
200 
0 00002 
1 2E-11 
4 17E+10 
8E-15 
2 4E-11 
2 4E-11 
0 000288 
2 884499 
Sample 2 
2 
1500 
1000 
2 
200 
0 00002 
12E-11 
167E+11 
8E-15 
6E-12 
6 01E-12 
0 000182 
1 817121 
Sample 3 
5 
1500 
1000 
5 
200 
0 00002 
1 2E-11 
4 17E+11 
8E-15 
2 4E-12 
2 41E-12 
0 000134 
1 338866 
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To show the result in 3D image we use Matlab 2007 to plot the image The 
program code is shown below 
%nanoparticles size and distance calculation 
%wntten by zhiguo zheng 
%PhD student of Biomedical Engmeenng of Louisiana Tech University% 
clc 
clear all 
%draw 3d sphere radius r nm in s nm cube cell 
[xsp,ysp,zsp] = sphere(20), 
r=200, 
d=1079, 
s=2000, 
xsp=xsp *r, 
ysp=ysp *r, 
zsp=zsp *r, 
for 1 = -s d s, 
forj=-s d s, 
for k=-s d s, 
surface(xsp+i,ysp+j ,zsp+k), 
end 
end, 
end, 
axis equal, 
view([50,20]), 
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The simulation results for 200 nm sphere pachtaxel nanoparticles at concentration of 
0 5 and 5 mg/mL are shown in Figure B-1 
Figure B-1 Simulation for 200 nm sephere sharp pachtaxel 
concentration at 0 5 mg/mL (left) and 5 mg/mL (right) 
%nanoparticles size and distance calculation 
%wntten by zhiguo zheng 
%PhD student of Biomedical Engineering of Louisiana Tech Umversity 
clc, clear all, 
%draw 3d cubes edge length r nm in distance d nm in a s nm cube cell 
x=[0 1 1 0 0 0,1 1 0 0 1 1,1 1 0 0 1 1,0 1 1 0 0 0], 
y=[0 0 1 1 0 0,0 1 1 0 0 0,0 1 1 0 1 1,0 0 1 1 1 1], 
z=[0 0 0 0 0 1,0 0 0 0 0 1,1 1 1 1 0 1,1 1 1 1 0 1], 
r=200, 
d=1339, 
s=3000, 
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x=x *r, 
y=y *r, 
z=z *r, 
for 1 = -s d s, 
forj=-s d s, 
for k--s d s, 
surface(x+i,y+j,z+k), 
end, 
end, 
end, 
axis equal, 
view([35,30]), 
The simulation results for 200 nm cube sharp pachtaxel nanoparticles at concentration 
of 0 5 and 5 mg/mL are shown in Figure B-2 
Figure B-2 Simulation for 200 nm cube sharp pachtaxel 
concentration at 0 5 mg/mL (left) and 5 mg/mL (right) 
APPENDLX C 
RELEASE MODEL FITTING 
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For release curve in Figure 7-2 we use OriginPro 8 1 software to fit the 
expenment data with modmg equation 
In this study, we use Ritger-Peppas' empirical Equation 
Figure C-l shows the fittmg of expenment result using Ritger-Peppas' empirical 
equation The fitting results are shown in Table C-l 
Table C-l Fitting results for the curcumin release profile 
Model 
Equation 
Reduced Chi-Sqr 
Adj R-Square 
Nano curcumin 
Nano curcumin 
Orginal curcumin 
Orginal curcumin 
Curcumin/(PS/BSA)2 
Curcumm/(PS/BSA)2 
Ritger-Peppas 
y = a*x 
3 48E-04 
0 99468 
a 
b 
a 
b 
a 
b 
1 80E-04 
0 99455 
Value 
0 34387 
0 21044 
11 00387 
0 01274 
0 18261 
0 24341 
4 49E-04 
0 99019 
Standard enor 
0 10581 
0 03356 
37 90579 
0 04171 
0 05416 
0 0346 
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100 200 300 
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400 500 
Figure C-l Fitting result for curcumin release 
Figure C-2 shows the fitting of experiment result using Ritger-Peppas' empirical 
equation The fittmg results are shown in Table C-2 
Table C-2 Fitting results for the pachtaxel release profile 
Model 
Equation 
Reduced Chi-Sqr 
Adj R-Square 
Nano pachtaxel 
Nano pachtaxel 
Orginal pachtaxel 
Orginal pachtaxel 
Pachtaxel/(PAH/BSA)2 
Pachtaxel/(PAH/BSA)2 
Ritger-Peppas 
Y = a V 
5 35939 
0 93758 
a 
b 
a 
b 
a 
b 
4 71E+00 
0 93513 
Value 
10 72209 
0 33469 
9 46E+00 
0 33125 
11 31214 
0 23387 
2 45E+00 
0 9103 
Standard Error 
1 38742 
0 02507 
1 27E+00 
0 02535 
1 30579 
0 02159 
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Nano pachtaxel 
Orginal pachtaxel 
pachtaxel /(PS/BSA)2 
-Fitting curve of nano pachtaxel 
-Fitting curve of orginal pachtaxel 
-Fitting curve of pachtaxel/(PS/BSA)2 
100 200 300 
time (mm) 
400 500 600 
Figure C-2 Fitting result for pachtaxel release 
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